Organised by what you are manufacturing.
Cell type determines the isolation target, the activation signal, the cytokine cocktail and the medium. Six workflows, each mapped to the reagent that sits at every step.
Engineered T cells, from apheresis to fill-finish
A matched isolation–activation–expansion set built around CD3/CD28 signalling, so your process development team can lock a single vendor for the critical reagents.






High-purity NK expansion without feeder cells
Kits that take PBMC or cord blood to high-purity NK populations, paired with the cytokines and CD16 mAbs needed for ADCC-competent products.






Consistent MSC expansion across donors
Xeno-free, phenol-red-free culture systems with the matrix and growth-factor pairings that keep doubling times and surface markers stable through passage 5.






Pluripotency you can audit
Defined matrices, laminin-511 E8 and small-molecule-adjacent growth factors for feeder-free maintenance and directed differentiation.






HSC expansion and gene correction
Early-acting cytokines for HSC maintenance during transduction, with the endotoxin control required for ex vivo gene therapy workflows.






Monocyte-derived DC and macrophage protocols
CD14⁺ isolation paired with GM-CSF / IL-4 maturation cocktails and TLR adjuvants for vaccine and immunotherapy research.






Working on something not listed here?
γδ T cells, TIL, CAR-macrophage, exosome manufacturing — the reagent set usually exists, it just is not a catalogue page yet. Tell us the process and we will map it.
